David Kurtz is the chief medical officer, head of research, and a cofounder of Foresight Diagnostics. His research focuses on developing and translating methods to detect, monitor, and treat hematologic malignancies. To accomplish this, he works at the intersection of molecular biology, cancer genomics, and bioengineering to develop the next generation of cancer diagnostics. Along with Ash Alizadeh, David was one of the earliest investigators to explore the utility of tumor-derived cell-free DNA in lymphomas. He has applied multiple methodologies to the detection of cell-free DNA in lymphomas, with a focus on improving the clinical utility and analytical sensitivity of these methods. Clinically, David is a medical oncologist who specializes in the treatment of non-Hodgkin lymphoma. His research program also focuses on the clinical translation of NGS tools and computational approaches for improving care for patients with all types of cancer.

Huw Ricketts has been working in the precision medicine field for more than 15 years. Having worked with multiple pharmaceutical companies whilst at QIAGEN, Huw moved to AstraZeneca to support their personalized medicine initiatives in oncology, working on novel companion diagnostic programs in breast, gastric and lung cancer with diagnostic partners. Huw then moved to NanoString, with a mission to get gene expression analysis adopted by pharmaceutical companies for the identification of patients most likely to benefit from their medicines. Returning to QIAGEN in 2015, Huw continued in the development of CDx assays for solid tumors. Especially interesting at this time where the partnerships with BMS for gene expression assay development and the building of an HPV CDx for use in head and neck cancer patients. Following a short period at Oncimmune (during the pandemic), Huw joined an exciting Cambridge UK-based company, Inivata. At Inivata, Huw lead the business development team taking the novel MRD technology into pharmaceutical partners. The Inivata MRD assay was able to detect very low levels of ctDNA in cancer patients, and Huw lead the introduction of that technology in pharmaceutical clinical trials. Since 2023, Huw has been back at QIAGEN working in the Partnering for Precision Medicine team, taking on three significant industry challenges; firstly the introduction of CDx in non-oncology diseases, secondly partnering with laboratories to enable CDx development and thirdly the development of precision diagnostic content on QIAGEN platforms such as the QIAcuityDx (digital PCR).